JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Начало・Списък с акции・Pacira Pharmaceuticals Inc-DE

Pacira Pharmaceuticals Inc-DE

Затворен

СекторЗдравеопазване

24.51 -3.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.2

Максимум

24.51

Ключови измерители
By Trading Economics
Приходи	-3.8M 1.6M
Продажби	17M 197M
P/E Средно за сектора	155.625 60.328
Марж на печалбата	0.832
Служители	825
EBITDA	-9.8M 25M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+12.2% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	77M 1.1B
Предишно отваряне	27.67
Предишно затваряне	24.51

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

24.83 / 26.38 Подкрепа & съпротива

Pacira Pharmaceuticals Inc-DE Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2026 г., 19:19 ч. UTC

Придобивния, сливания и поглъщания

Intertek Group Rejects EQT's Revised Offer

24.04.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Scoring the Cook Era -- Barrons.com

24.04.2026 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

24.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:09 ч. UTC

Печалби

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24.04.2026 г., 19:48 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24.04.2026 г., 19:22 ч. UTC

Печалби

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24.04.2026 г., 19:06 ч. UTC

Печалби

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24.04.2026 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24.04.2026 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24.04.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

Intertek Rejects Revised EQT Offer

24.04.2026 г., 18:12 ч. UTC

Пазарно говорене

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24.04.2026 г., 18:06 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24.04.2026 г., 17:42 ч. UTC

Печалби

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Печалби

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Пазарно говорене

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24.04.2026 г., 17:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

24.04.2026 г., 17:11 ч. UTC

Пазарно говорене

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24.04.2026 г., 17:09 ч. UTC

Пазарно говорене

Печалби

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24.04.2026 г., 17:09 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 17:06 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24.04.2026 г., 16:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

24.04.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pacira Pharmaceuticals Inc-DE Прогноза

Ценова цел

By TipRanks

12.2% нагоре

12-месечна прогноза

Среден 27.5 USD 12.2%

Висок 38 USD

Нисък 22 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Pacira Pharmaceuticals Inc-DE през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Pacira Pharmaceuticals Inc-DE през последните 3 месеца.

Техническа оценка

By Trading Central

24.83 / 26.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.